Gabriela Hobbs/Massachusetts General Hospital
Sep 4, 2025, 18:00
SOHO 2025: Gabriela Hobbs on Emerging Strategies for Managing Polycythemia Vera and Essential Thrombocythemia
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | PRESENTATION
Gabriela Hobbs, Massachusetts General Hospital News
Discusses novel therapies in development for treatment of Polycythemia Vera, including modulators of hepcidin-ferroportin, bomedemstat, givinostat, and novel JAKis, and in Essential Thrombocythemia, including ropeginterferon, bomedemstat, and CALR-directed agents.
Follow our live feed for more updates.”
Find more slides in the gallery.
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 15:02Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:50Steve Tuplin on Roche’s Mission at ASH25
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 5, 2025, 03:46Sreeni Sivan Pillai: Preventing Thrombophlebitis and Upper Limb DVT in PICC Lines